Equine Familial Isolated Hypoparathyroidism (EFIH)
Gene or Region: RAPGEF5
Reference Variant: C
Mutant Variant: A
Affected Breeds: Thoroughbred, Thoroughbred crosses, other Thoroughbred-influenced breeds
Research Confidence: High - Strong association in studied population
Explanation of Results: efih/efih = homozygous for Equine Familial Isolated Hypoparathyroidism, trait expressed efih/n = heterozygous for Equine Familial Isolated Hypoparathyroidism, carrier n/n = no variant detected
Equine Familial Isolated Hypoparathyroidism (EFIH): What You Need to Know Before Breeding Thoroughbreds
Equine Familial Isolated Hypoparathyroidism (EFIH) is a fatal genetic disorder identified in Thoroughbred foals, characterized by low blood calcium levels leading to muscle stiffness, seizures, and, ultimately, death. The condition is inherited in an autosomal recessive manner, meaning that foals with two copies of the causative genetic variant are affected.
EFIH manifests in foals up to 35 days old, presenting with symptoms such as involuntary muscle contractions, a stiff gait progressing to an inability to stand, seizures, fever, and rapid pulse. These clinical signs are associated with low blood calcium concentrations and inadequately low or normal parathyroid hormone levels. Necropsy findings often reveal underdeveloped or absent parathyroid glands.
Gene Information
The genetic basis for EFIH is a nonsense variant in the Rap Guanine Nucleotide Exchange Factor 5 gene (RAPGEF5) that replaces a serine in the protein product with a stop codon (c.2624C>A p.Ser875*), leading to a truncated protein with decreased functionality. RAPGEF5 plays a crucial role in intracellular signaling pathways, particularly those involved in cyclic AMP (cAMP)-dependent signaling and calcium homeostasis. In affected horses, this variant in RAPGEF5 disrupts normal parathyroid gland function, impairing PTH synthesis and secretion.
References
Rivas, V. N., Magdesian, K. G., Fagan, S., Slovis, N. M., Luethy, D., Javsicas, L. H., Caserto, B. G., Miller, A. D., Dahlgren, A. R., Peterson, J., Hales, E. N., Peng, S., Watson, K. D., Khokha, M. K., & Finno, C. J. (2020). A nonsense variant in Rap Guanine Nucleotide Exchange Factor 5 (RAPGEF5) is associated with equine familial isolated hypoparathyroidism in Thoroughbred foals. PLoS Genetics, 16(9), e1009028. doi: 10.1371/journal.pgen.1009028
More Horse Health
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.
Glycogen Branching Enzyme Deficiency
Glycogen Branching Enzyme Deficiency (GBED) is a lethal recessive disorder characterized by seizures, muscle weakness, respiratory failure, and death. Many affected foals do not make it full term and are aborted or stillborn. Carriers (gbed/n) have no known issues.
Hereditary Equine Regional Dermal Asthenia
Hereditary Equine Regional Dermal Asthenia (HERDA) is a degenerative skin disease that primarily affects the American Quarter Horse. Loose skin is often an early indication of the disease, and severe seromas, hematomas, ulcerations usually develop around 1.5 years of age. There is no cure, and the majority of affected animals have to be euthanized within 2-4 years.